News & Events

SKIN treatment specialist Peplin has reported "positive" results from a late-stage clinical trial of its gel to treat pre-cancerous sun spots...

> Read More

> Read More

> Read More

> Read More

> Read More

Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)". This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, the…

> Read More

> Read More

Biotechnology company Hatchtech Pty Ltd today announced that Paul MacLeman has resigned as Chief Executive Officer and Director. The company congratulates Dr MacLeman who is leaving to take up the CEO role at a high profile publicly listed biotechnology company. Since…

> Read More

Sunshine Heart (ASX: SHC), a global medical device company focused on innovative heart assist technologies announced today that The Ohio State University Medical Center in Columbus, Ohio has successfully completed the first two implants of the Company's C-PulseTM heart assist system under a…

> Read More

> Read More

-- New Data Published in Leukemia Showed 90% Kill of Leukemic Stem Cells and Prolonged Survival in Mice with Resistant CML - Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are…

> Read More

Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)". This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, the…

> Read More

Dear Arana Shareholder, I am writing to you to ensure you are up to date with several important developments for Arana Therapeutics Limited ("Arana"). As you may already be aware, on 27 February 2009 Cephalon, Inc. (Nasdaq: CEPH) announced that its wholly-owned…

> Read More

Cephalon, Inc. (Nasdaq: CEPH) today announced that its wholly-owned subsidary, Cephalon International Holdings, Inc., intends to make a cash takeover offer for all of the shares in Arana Therapeutics Limited which it does not already own (ASX: AAH) ("Arana") at a minimum price of $1.40 per…

> Read More

CogState Ltd (ASX:CGS) and United BioSource Corporation (UBC) announced today that they will not renew the strategic relationship the two companies initiated in 2008 to co-market and co-deliver CogState's ClinicalTrials software for computerized cognitive testing in clinical trials. …

> Read More

Met primary efficacy endpoint with statistically significant complete clearance rate of AK lesions vs. vehicle Reduction in overall lesion count in all active treatment groups Well-tolerated, rapidly resolving local skin responses at all concentrations and durations …

> Read More

Xenome Limited ("Xenome") today announced it has executed a research licence agreement with MedImmune LLC (MedImmune"), a wholly owned subsidiary of AstraZeneca. Under the partnership MedImmune will gain access to Xenome's xdiscoverT venom peptide library to exclusively…

> Read More

Plantronics Discovery 925 beats competitors from Jawbone, BlueAnt and Motorola in an independent consumer research study performed by 7B Labs. 7B Labs announced today that the Plantronics Discovery 925 has won its Premium Bluetooth Headset Challenge, beating out the Aliph…

> Read More

Nuon Therapeutics, Inc., a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, today announced the appointment of Michael M. Kitt, M.D., to the position of Chief Medical Officer. "Dr. Kitt is an…

> Read More

Sunshine Heart (ASX: SHC) announces the retirement of Malcolm McComas as a director of the Company effective 16 December 2008. Mr McComas was chairman of Sunshine Heart, Inc. from its listing on the ASX in September 2004 until its last annual general meeting on 30 October…

> Read More

Peplin, Inc. (ASX:PLI) today announced the completion of enrolment of its 250 patient pivotal Phase III US and Australian clinical trial in actinic (solar) keratosis (AK), a common pre-cancerous skin condition affecting between 40 and 60 percent of adult Australians and accounting for at…

> Read More

aloBios Pharmaceuticals, Inc. today announced that the company has raised an additional $12 million in the second closing of its Series D venture financing, which along with the $20 million it raised in September brings the round to $32 million. This tranche was dominated by a new…

> Read More

ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today positive interim clinical data from 44 patients enrolled in its ongoing phase 2/3 trial of omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients with the T315I mutation. Clinical investigators reported…

> Read More

Hatchtech Pty Ltd has secured $2.5 million in further funding from the University of Melbourne Endowment Trust (advised by GBS Venture Partners) and from Uniseed. The investment will be used to progress its unique head lice treatment into Phase II safety/efficacy studies in humans. The new…

> Read More

Sunshine Heart, Inc. (ASX: SHC) announces that the Institutional Review Board (IRB) of the Jewish Hospital, University of Louisville, Kentucky has approved the hospital's participation in the US clinical trial for C-PulseTM. The trial has been fully approved by the US Food and Drug…

> Read More